Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 2143 • ACR Convergence 2025
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Jacqueline Madison¹, Andrew Grim² and Janna Shim³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medicine, Ann Arbor, MI, ³Midwestern University Chicago College of Osteopathic Medicine, Downers Grove
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are rare, chronic, autoinflammatory diseases distinct from other forms of chronic inflammatory arthritis. Potential…
Abstract Number: 1821 • ACR Convergence 2025
Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis
Donna Do¹, Brandon Michalidas², Mariia Pavlenko³, Alexandra Duell², Sheila Angeles-Han⁴ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) is a potentially sight-limiting complication of pediatric rheumatic diseases, including juvenile idiopathic arthritis. However, the underlying inflammatory biology of CAU…
Abstract Number: 0819 • ACR Convergence 2025
Subcellular resolution spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis
Jun Inamo¹, Roselyn Fierkens², Michael Clay², Clara Lin³, Kari Hayes², Nathan Rogers⁴, Heather Leach² and Kentaro Yomogida², ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado, Aurora, CO, ³Children's Hospital Colorado, Aurora, CO, ⁴Children’s Hospital Colorado, Aurora, CO
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease, yet the spatial immune architecture of inflamed synovium remains poorly characterized. Prior…
Abstract Number: 0410 • ACR Convergence 2025
Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program
Julia Harris¹, Emily Fox², Leslie Favier³, Michael Holland², Susan Parish⁴, Cara Hoffart⁴, Maria Ibarra², Jordan Jones⁴, Luke Harris⁴, Kristy Diederich⁴, Rachel Moran⁴, Amy Vickers⁴, Hannah Maasen⁴, Lydia Ottaviano⁴, Carlie Baldus⁴, Krysten Potter⁴, Melissa Erpelding⁴, Stephanie Quinn⁴ and Ashley Cooper⁴, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Hospital, Kansas City, MO, ³Childrens mercy Hospital - Kansas City, Leawood, KS, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Outcomes for patients with juvenile idiopathic arthritis (JIA) are suboptimal with many patients having active disease, functional limitations, significant pain, and decreased health-related quality…
Abstract Number: 0389 • ACR Convergence 2025
An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
Alessandra Alongi¹, Hermine Brunner², Angelo Ravelli³, Tadej Avcin⁴, Michael Beresford⁵, RUBEN BURGOS-VARGAS⁶, Ruben Cuttica⁷, Raju Khubchandani⁸, Ronald laxer⁹, Seza Özen¹⁰, Ross Petty¹¹, Carol Wallace¹², Nico Wulffraat¹³, Silvia Magni-Manzoni¹⁴, Marija Jelusic¹⁵, Alessandro Consolaro¹⁶, Jordi anton¹⁷, Gerd Horneff¹⁸, Mia Glerup¹⁹, Giovanni Filocamo²⁰, Gabriele Simonini²¹, ADELE CIVINO²², Agustin Remesal²³, Silvia Scala²⁴, Angela Pistorio²⁵, Daniel Lovell², Alberto Martini²⁶ and Nicolino Ruperto²⁷, ¹Università Milano Bicocca, Milan, Italy, Milano, Italy, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ⁴University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶Department of Rheumatology, Hospital General de Mexico, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de México, Mexico, ⁷Hospital Pedro de Elizalde, Buenos Aires, Argentina, ⁸Jaslok Hospital and Research Center, Mumbai, India, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Hacettepe University Medical Faculty, Ankara, Turkey, ¹¹British Columbia Children’s Hospital, University of British Columbia, Vancouver, ON, Canada, ¹²Seattle Children's Hospital, University of Washington, Seattle, WA, ¹³Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁴Bambino Gesù IRCCS Children's Hospital, Rome, Italy, ¹⁵University Hospital Centre Zagreb, Zagreb, Croatia, ¹⁶IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹⁷Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, ¹⁸Asklepios Klinik, Hamburg, Germany, ¹⁹Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, ²⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ²²Department of Pediatric Immunology and Rheumatology, LECCE, Italy, ²³Hospital Universitario La Paz, Madrid, Spain, ²⁴Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁵Servizio di Epidemiologia e Biostatistica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁶Università degli Studi di Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy
Background/Purpose: To improve the current classification criteria for juvenile idiopathic arthritis (JIA), a multi-step initiative coordinated by PRINTO was launched in 2015, starting with a…
Abstract Number: 2140 • ACR Convergence 2025
Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
Haeja Kessler¹, Noel Gibson¹, Alyssa Sproles², Celine Lages¹, Paul Dascani³, Sherry Thornton⁴ and Grant Schulert⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cytek Biosciences, Pittsburgh, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique subtype of juvenile idiopathic arthritis with life threatening complications including macrophage activation syndrome and chronic lung…
Abstract Number: 1820 • ACR Convergence 2025
Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
Taskin Sabit¹, Minyi Yu², Joy Baker¹, Sanjeev Dhakal³, Sam Chiang⁴, Scott Canna⁵, Randy Cron⁶, Lauren Henderson⁷, Karen Onel⁸, Mona Riskalla⁹, Tiphanie Vogel¹⁰, Pui Lee¹¹, Grant Schulert² and Alexei Grom², ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children hospital, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnnati, OH, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Boston Children's Hospital, Watertown, MA, ⁸HSS, New York, NY, ⁹University of Minnesota Masonic Children's Hospital, Minneapolis, MN, ¹⁰Baylor College of Medicine, Houston, TX, ¹¹Boston Children's Hospital, Newton, MA
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is a severe inflammatory disorder that affects the joints as well as other organ systems, with complications including Macrophage…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Jordan Jones², Michael Holland³, Cara Hoffart², Maria Ibarra³ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…
Abstract Number: 0387 • ACR Convergence 2025
Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health
William Soulsby¹ and Carolina Tamashiro², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Juvenile arthritis (JA) is characterized by joint pain, stiffness, and decreased mobility, potentially affecting participation in physical activity (PA). Current guidelines from the CDC…
Abstract Number: 2138 • ACR Convergence 2025
Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Francesco Baldo¹, Greta Rogani², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Marija Jelusic⁶, Jordi Anton⁷, Paul Brogan⁸, Scott Canna⁹, Randy Cron¹⁰, Fabrizio De Benedetti¹¹, Alexei Grom¹², Merav Heshin Bekenstein¹³, AnnaCarin Horne¹⁴, Raju Khubchandani¹⁵, Mao Mizuta¹⁶, Seza Özen¹⁷, Pierre Quartier Dit Maire¹⁸, Angelo Ravelli¹⁹, Masaki Shimizu²⁰, Grant Schulert¹², Christiaan Scott²¹, Rashmi Sinha²², Nicolino Ruperto²³, Joost Swart²⁴, Bruno Fautrel²⁵, Sebastiaan Vastert² and Francesca Minoia²⁶, ¹ASST-Pini-CTO, Milano, Milan, Italy, ²University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁴University Hospital Muenster, Muenster, Germany, ⁵IRCCS G. Gaslini, Genova, Genoa, Italy, ⁶University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁷Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁸UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ¹⁴Karolinska University Hospital, Sollentuna, Sweden, ¹⁵SRCC Childrens Hospital Mumbai, Mumbai, India, ¹⁶Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, ¹⁷Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁸Necker hospital, Paris Cedex ¹⁵, France, ¹⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ²⁰Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, ²¹Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²²Systemic JIA Foundation, Cincinnati, OH, ²³Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ²⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous improvement in care and the recent update of international recommendations, relevant discrepancies in the diagnostic and treatment approach to Still’s disease (SD)…
Abstract Number: 1813 • ACR Convergence 2025
Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
Abigail Thielbar¹, Tracy Ting², Lexi Auld³, Kelly Rogers⁴, Megan Quinlan-Waters⁵, Sheila Angeles-Han⁴, Ekemini Ogbu², Daniel Lovell², Jennifer Huggins⁶, Grant Schulert², Yuriy Baglaenko⁴ and Patricia Vega-Fernandez², ¹Cincinnati Children's Hospital, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is characterized by joint pain and inflammation. Persistent oligoarticular JIA(oligoJIA) is defined by the involvement of up to 4 joints…
Abstract Number: 0426 • ACR Convergence 2025
Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
Vicenç Torrente-Segarra¹, Andrea Zacarias², Cynthia Rojas³, Jordi Antón-López², Judith Sanchez⁴ and Meritxell Salles Lizarzaburu⁵, ¹Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ²Pediatric Rheumatology Department, Hospital Sant Joan de Déu, Barcelona (Spain)., Barcelona, Spain, ³Rheumatology Department, Hospital Comarcal Alt Penedès Garraf, Vilafranca del Penedès (Spain)., Vilafranca del Penedes, Spain, ⁴Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ⁵Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain
Background/Purpose: This study aims to evaluate the efficacy and safety of tofacitnib, a JAK inhibitor, in a multicentric cohort of patients with juvenile idiopathic arthritis…
Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Ilaria Maccora¹, Margaret Chang², Sheila Angeles-Han³, Andrea Taddio⁴, Lampros Fotis⁵, Cinzia de Libero⁶, Madison Mangin⁷, Alexandra Duell⁸, Marco Gabrielli⁹, Kyveli Chiotopoulou⁵, Lillian Sutton¹⁰, Virginia Miraldi Utz⁸ and Gabriele Simonini¹¹, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Boston Children's Hospital, Boston, MA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, ⁶Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, ⁷Boston Children's Hospital, St Simons Island, GA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹University of Trieste, Trieste, Italy, Trieste, Italy, ¹⁰Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, ¹¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
Abstract Number: 0312 • ACR Convergence 2025
Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis
Kainat Jahangir¹, Meer Murtaza², Rida Ul Jannat³, Muhammad Arham⁴, Najam Gohar⁵, Faseeh Haider⁶, Rohma Ahmed⁷, FNU Raja⁸, Rabie Habib⁹, Mahnoor Umar¹⁰, Hira Saleem¹¹, Faizan Ahmed¹², Tehmasp Mirza¹³, Momina Siddiqui¹⁴, Muhammad Umer¹⁵, Haziq Ahmed¹⁶, Maryam Anwar¹⁷, Rehab Bint e Tahir¹⁸, Yusra Junaid¹⁹ and Ramsha Ali²⁰, ¹Dow Medical College, Karachi, Pakistan, ²Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, ³Wake Forest University, Winston Salem North Carolina, Winston-Salem, NC, ⁴Sheikh Zayed Medical College, Lahore, Pakistan, ⁵Ameer Ud Din Medical College, Sialkot, Pakistan, ⁶Allama Iqbal Medical college, Lahore, Punjab, Pakistan, ⁷Fatima Jinnah Medical University, Lahore, Pakistan, ⁸Federal Medical and Dental College, Islamabad, Pakistan, ⁹Baylor College of Medicine, Texas, Pakistan, ¹⁰Nassau University Medical Center, New York, ¹¹Houston Methodist Hospital, Texas, ¹²Corewell health, dearborn, MI, ¹³Shalamar Medical and Dental College, Lahore, Pakistan, ¹⁴Rawalpindi Medical Univeristy, Rawalpindi, Punjab, Pakistan, ¹⁵King Edward Medical College, Lahore, Pakistan, ¹⁶Sheikh Khalifa bin zayed Alnahyan Medical College, Lahore, Punjab, Pakistan, ¹⁷Baqai Medical University, Karachi, Pakistan, ¹⁸-, lahore, ¹⁹Dow University of health and sciences, karachi, Pakistan, ²⁰Peoples University of Medical and Health Sciences SBA, NawabShah, Pakistan
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses various chronic inflammatory conditions in children that lead to joint discomfort and potential disability. Tocilizumab, an antibody targeting interleukin-6,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].